1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Eurobio-Scientific SA

Eurobio-Scientific SA

25.60
EUR
+0.10
(+0.39%)
254.37MMarket Cap
Apr 14Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.8
10.09
8.41
7.24
4.9
5.16
5.42
16.85
17.03
13.45
11.66
15.08
16.45
- -
Basic EPS, GAAP
-2.11
-1.77
-1.66
-1.98
-1.14
-0.28
0.29
6.56
5.58
2.2
0.43
0.39
0.47
- -
Free Cash Flow per Basic Share
-1.92
-1.3
-0.73
-0.9
-0.16
-0.22
0.31
4.7
5.91
3.55
2.04
1.31
0.61
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7.05
6.16
4.63
1.33
3.28
2.99
3.25
9.51
14.18
16.92
17.44
17.82
18.27
17.82
Tangible Book Value per Share
1.52
1.91
1.39
0.14
-0.41
-0.24
0.57
7.18
12.26
1.76
2.19
2.52
3.22
2.52
Basic Weighted Avg Shares
3
3
4
4
9
10
11
11
11
11
11
10
10
10
Sales/Revenue/Turnover
31
31
30
28
43
51
59
189
185
153
130
155
169
- -
Operating Margin (%)
-22.84
-18.18
-27.92
-26.09
-13.47
-2.3
0.96
43
37.96
20.23
7.8
6.34
6.37
- -
Depreciation Expense
2
3
2
2
6
6
7
7
7
9
14
17
17
- -
Net Income, GAAP
-6
-5
-6
-8
-10
-3
3
73
61
25
5
4
5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
9.16
15.1
15.99
30.71
36.39
37.66
- -
Profit Margin (%)
-19.49
-17.54
-19.68
-27.3
-23.21
-5.48
5.34
38.91
32.78
16.34
3.72
2.59
2.89
- -
Working Capital
5
14
11
2
6
8
9
87
137
91
91
48
45
48
LT Debt
2
8
6
2
14
15
11
15
11
99
86
10
12
10
Total Equity
21
21
18
12
32
30
37
108
161
173
175
179
184
179
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
71.48
35.97
10.8
2.4
3.45
3.22
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
76.04
38.61
11.19
2.79
2.83
3.1
- -
Return on Common Equity (%)
-26.6
-26.44
-30.14
-51.06
-45.41
-9.03
9.53
101.77
45.06
14.94
2.78
2.26
2.68
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
15
15
3
LT Borrowings
82
75
10
LT Finance Leases
4
3
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
163
139
254

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
144
147
90
Cash, Cash Equivalents & STI
89
87
23
Accounts Receivable, Net
27
29
33
Inventories
21
23
27
Total Current Liabilities
53
55
41
Payables & Accruals
- -
- -
- -
ST Debt
15
15
3
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.16%
12.58%
2.83%
Free Cash Flow
106.38%
-30.62%
-53.28%
Net Income, GAAP
185.22%
-30.53%
21.69%
Sales/Revenue/Turnover
29.43%
-1.28%
9.08%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
130
2024
- -
- -
155
2025
- -
- -
169

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.43
2024
- -
- -
0.39
2025
- -
- -
0.47

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Denis Fortier
Full Time Employees
343
Sector
Health technology
Industry
Medical specialties
Address
7 avenue de Scandinavie Les Ulis IF France 91953
IPO Date
Nov 18, 2005
Website
eurobio-scientific.fr
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Eurobio Scientific S.A. (ALERS.PA) develops, manufactures, and commercializes specialty in vitro diagnostic tests and products for clinical and research use, with a diversified portfolio spanning transplantation, infectious diseases, life sciences, and oncology. Core offerings include reagents and software for transplant matching and chimerism monitoring, culture media for cornea graft transplants, prognostic genomic tests for breast and prostate cancer, genetic molecular tests for infectious diseases, fertility, and dermatological conditions, cell culture media, quality controls, and serology products for infectious and autoimmune diseases under brands such as GenDx, GenBio, AlloMap, TQS (Tetanus Quick Stick), and EBX molecular biology family. The company also distributes third-party in vitro diagnostic products through its extensive network and provides dedicated reagents to pharmaceutical, biotechnology, and research laboratories. Headquartered in Les Ulis, in the Paris region of France, Eurobio Scientific operates production units in France, Germany, the Netherlands, and the United States, with subsidiaries and affiliates across more than 10 countries including the US (San Diego and Chicago), UK, Germany, Switzerland, Belgium, Italy, and the Netherlands. Founded in 1962, the group employs over 360 people worldwide, including 50 R&D scientists, and generates more than 30% of revenues from proprietary products it designs and produces. Recent major developments include the December 2024 takeover bid by EB Development, supported by NextStage AM and IK Partners, which secured 88.9% of the share capital to accelerate growth and external expansion in in vitro diagnostics and intelligent health markets. The company completed the acquisition of the Life Science unit of Voden Medical Instruments S.p.A. in Italy in March 2025, alongside prior strategic purchases such as GenDx in August 2022—a global leader in HLA typing for transplant compatibility—and integrations of DID Diagnostic International and Alpha Biotech. These moves, backed by NextStage AM since May 2022, strengthen proprietary product lines, management structure, and post-Covid transformation toward becoming a leading global specialty diagnostics provider.